SFC

Découvrez l'article du mois de mars des Archives of Cardiovascular Diseases, la revue scientifique en anglais de la SFC : 
Usefulness of perioperative transoesophageal echocardiography during paediatric cardiac surgery 
Pierrick Pyra, Khaled Hadeed, Aitor Guitarte Vidaurre, Rémi Vincent, Yves Dulac, Gérald Chausseray, David Felice Calvaruso, Philippe Acar, Clément Karsenty

Abstract


Background: Paediatric transoesophageal echocardiography probes allow perioperative evaluation during paediatric congenital heart disease surgey.

Aim: To assess the usefulness of perioperative transoesophageal echocardiography in evaluating the severity of residual lesions, based on the type of congenital heart disease repaired in paediatric patients.

Methods: A retrospective analysis was conducted on paediatric patients who underwent open-heart surgery at our tertiary centre over a four-year period. Perioperative transoesophageal echocardiography studies were performed, and residual lesions were classified as mild, moderate or severe.

Results: Overall, 323 procedures involving 310 patients with a median age of 13.8 (0.07-214.4) months and a median weight of 8.2 (2-96) kg at intervention were enrolled in the study. Twenty-one (6.5%) residual lesions led to immediate reintervention: severe right ventricular outflow tract obstruction (n=12); severe aortic regurgitation (n=3); superior vena cava stenosis (n=2); moderate residual ventricular septal defect (n=2); severe mitral regurgitation (n=1); and severe mitral stenosis (n=1). Three (0.9%) neonates had ventilation difficulties caused by the transoesophageal echocardiography probe having to be removed, but experienced no sequelae.

Conclusion: Perioperative transoesophageal echocardiography is a safe procedure, providing information on severe residual lesions, leading to the immediate revision of several paediatric congenital heart disease cases.

Nos suggestions d’actualités

Les actualités Cardio Online

Muvalaplin : nouvel inhibiteur de la lp(a) par voie orale

21 novembre 2024

Pas de supériorité d’un système d’aide à la décision pour optimiser les thérapies hypolipémiantes dans le post SCA

21 novembre 2024

Efficacité et sécurité d’emploi de l’obicetrapib, un nouvel inhibiteur de la CETP

21 novembre 2024

Zerlasiran, encore un nouvel antiLp(a) en développement

21 novembre 2024

L’edoxaban pour la prévention de thrombose valvulaire

20 novembre 2024

21/11/2024
Actualités Communautés
Newsletter

Newsletter de la SFHTA - Novembre 2024

21/11/2024
Actualités Congrès
Congrès

Impact environnemental de la cardiologie : Participez à notre enquête nationale !

20/11/2024
Actualités Communautés
Communautés

Congrès FCPC 2027 et 2028 : Appel à candidatures